TRENTIN, Leonardo
 Distribuzione geografica
Continente #
EU - Europa 208
NA - Nord America 115
AS - Asia 38
Totale 361
Nazione #
US - Stati Uniti d'America 115
IE - Irlanda 104
SE - Svezia 51
DE - Germania 27
HK - Hong Kong 22
IT - Italia 11
SG - Singapore 10
CZ - Repubblica Ceca 5
UA - Ucraina 5
IN - India 4
CN - Cina 2
FI - Finlandia 2
FR - Francia 2
GB - Regno Unito 1
Totale 361
Città #
Dublin 104
Hong Kong 22
Bremen 13
Chandler 13
Lawrence 13
Princeton 13
Boardman 11
Jacksonville 10
Brno 5
Singapore 5
Dearborn 4
Somaglia 4
Munich 3
Piemonte 3
Beijing 2
Gunzenhausen 2
Helsinki 2
San Mateo 2
Wilmington 2
Arona 1
Cagliari 1
Grafing 1
Naples 1
Norwalk 1
Palermo 1
Sacramento 1
Totale 240
Nome #
Genetic Landscape of Ultra-Stable Chronic Lymphocytic Leukemia Patients 52
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 34
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 32
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 32
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 29
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 26
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 26
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 25
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 24
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 24
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 24
IRF4 L116R mutation promotes proliferation of chronic lymphocytic leukemia B cells inducing MYC 24
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 23
Totale 375
Categoria #
all - tutte 2.796
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.796


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202013 0 0 1 0 2 1 4 0 2 2 1 0
2020/202117 1 0 1 0 3 2 3 0 3 1 3 0
2021/202247 0 0 2 1 2 0 1 0 3 1 11 26
2022/2023211 13 12 19 0 14 15 1 20 104 1 5 7
2023/202479 5 8 5 2 12 0 22 0 0 0 3 22
2024/20253 3 0 0 0 0 0 0 0 0 0 0 0
Totale 375